Work in progress

  • The Effects of Cost-sharing on Health Care and Prescription Drug Utilization
    • Joint work with Niklas Jakobsson and Naimi Johansson

We are conducting a couple of different studies where we use quasi-experimental approaches (regression-kink and regression-discontinuity designs) to estimate the causal impact of cost-sharing on health care and pharmaceutical consumption. We also study if individual demographic and socio-economic factors, such as gender, family, ethnic background, education and income, as well as the type of health care matter for the (potential) effect of patient copayments.

  • Regional Variation in Health Care Utilization
    • Joint work with Niklas Jakobsson and Naimi Johansson

Differences in health care utilization and spending across regions may be considered valid if differences are driven due to health needs, i.e. if people in one region are in general very healthy we would expect a lower level of health care utilization than a region with generally less healthy people. On the other hand, if the variation across entities cannot be explained by differences in need and preferences, it can be a sign of misallocation of resources, unnecessary overuse and inefficiency. In Sweden (year 2015) the county council average number of visits to a physician in primary care ranged from 1.1 to 2.0, and visits to an outpatient specialist ranged from 0.9 to 1.6. In this project we are trying to disentangle the share of regional differences in health care utilization that can be explained by demand- and supply-factors, respectively.

  • Cost-Effectiveness and Primary Care Treatments for Mild to Moderate Depression
    • Joint work with Anna Holst and Cecilia Björkelund

We are conducting cost-effectiveness studies alongside two RCTs in the primary care setting, one assessing web-based Cognitive Behavioral Therapy (Web-CBT) and the other assessing a care-manger program to facilitate better treatment effectiveness for patients with mild to moderate depression. Both interventions are compared to “treatment as usual” and can be characterized as randomized pragmatic effectiveness trials.

  • Health risk valuation
    • Joint work with Arne Risa Hole and Henrik Andersson

We are preparing a paper for the Oxford Encyclopedia on Health Risk Valuation. Many public policies and individual actions have consequences for the health of the population. In order to understand if a (costly) policy to improve population health is a wise use of resources, analysts can utilize economic evaluation methods in order to compare the benefits and costs of the policy. In order to assess the welfare effects it is essential that the costs and benefits are evaluated using the same metric, where a monetary metric often is used for convenience. Money measures of a change in health are theoretically derived using the concepts of Equivalent Variation and Compensating Variation. This paper will review the theory, methods and applications of state-of-the-art health risk valuation.